gms | German Medical Science

76. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

04.05. - 08.05.2005, Erfurt

Prestimulation of Head and Neck Cancer Cells with Growth Factors effects enhanced Treatment Efficacy

Meeting Abstract

  • corresponding author Markus Hambek - ENT-Center, University Frankfurt, Frankfurt/Main
  • Christian Werner - ENT-Center, University Frankfurt, Frankfurt/Main
  • Mehran Baghi - ENT-Center, University Frankfurt, Frankfurt/Main
  • Wolfgang Gstöttner - ENT-Center, University Frankfurt, Frankfurt/Main
  • Rainald Knecht - ENT-Center, University Frankfurt, Frankfurt/Main

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. 76. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e.V.. Erfurt, 04.-08.05.2005. Düsseldorf, Köln: German Medical Science; 2005. Doc05hno663

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/hno2005/05hno157.shtml

Veröffentlicht: 22. September 2005

© 2005 Hambek et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Background: Treatment of squamous cell carcinomas of the head and neck consists of surgery, radiation and/or chemotherapy. However, despite complete remission of the disease, many patients suffer from recurrences during a follow up period of 2 years.

Methods: Il-6, Serotonin, G-CSF and EGF were used to stimulate G0-phase head and neck cancer cells before treatment with Cisplatin. The proportion of G0-phase cells has been detected by multi color FACS analysis and Ki67 staining.

Results: The combination of highest efficacy to provoke cell cycle reentry has been Serotonin + EGF. This combination has then been used to stimulate cancer cells for chemotherapy with cisplatin. The total amount of G0 phase cells has been significantly reduced after 2-fold Serotonin/EGF coincubation. The prestimulation group showed a significant reduced amount of G0-cells. Furthermore, the total amount of A431, Detroit 562 and UM-SCC 10B cells has been significantly reduced in the prestimulation group compared to the control and cisplatin (without prestimulation) group.

Conclusions: Our investigation demonstrates for the first time that G0 cells of head and neck carcinomas are available for treatment after targeted stimulation with growth factors. This provides a new insight in tumor physiology and should lead to reconsideration of established treatment regimen.